Heart failure test kit MMP-9

plasmaELISAlyophilized

Firalis MMP-9 ELISA kit is intended to be used for the in vitro quantification of human MMP-9 in human EDTA plasma samples as an aid for diagnosis of the risk of heart failure with reduced ejection fraction (HFrEF) with left ventricular ejection fraction (LVEF) < 40% in patients after first acute myocardial infarction (AMI) and treated by percutaneous intervention (PCI). MMP-9 is part of the matrix metalloproteinase family presenting a group of structurally related zinc-containing proteolytic enzymes, playing an important role in tissue remodeling of extracellular matrix. MMP-9 is a 92 kDa protein with a sequence length of 707 amino acids that is produced by epithelial cells and is stored in the secretory granules of neutrophils and eosinophils. It has been shown to mediate vascular leakage and to initiate the migration of inflammatory cells inducing wound repair. Several pre-clinical studies suggest that MMP-9 has the potential to predict, diagnose and prognosticate cardiac remodeling and related events. For example, MMP-9 null mice after MI were completed protected against cardiac rupture and demonstrated decrease in collagen & macrophage infiltration in cardiac tissue that resulted eventually in decrease in left ventricular dimentions, a hallmark of cardiac remodeling. Targeted inhibition of MMPs attenuated left ventricular remodeling in experimental MI. In ageing CB6F1 mice, increase in MMP-9 correlated with increase in LV dimensions and wall thickness and after MI result in increased neovascularization clinical data has demonstrated that MMP-9 diagnoses the risk of heart failure in patients who have suffered AMI.